Johnson & Johnson items findings from the most important Eu real-world dataset for esketamine nasal spray (NS) which ascertain its effectiveness and tolerability in a real-world affected person inhabitants, which on moderate had critical, power, treatment-resistant melancholy (TRD).
The learn about gives distinct new perception into the sturdiness of medication impact, with symptom steadiness maintained throughout 6 months following discontinuation of esketamine NS.
BEERSE, BELGIUM, March 28, 2026 (GLOBE NEWSWIRE) — Johnson & Johnson nowadays introduced new information from the ECHO learn about which fortify the effectiveness and protection profile of SPRAVATO® (esketamine NS) and point out sturdiness of medication impact throughout 6 months after medication discontinuation in a real-world atmosphere for sufferers with TRD. Those information are being offered at this 12 months’s Eu Psychiatric Affiliation (EPA) Congress, happening March 28-31, in Prague, Czech Republic.
Key learn about findings fortify tough effectiveness of esketamine NS
From throughout Europe and Israel, 570 sufferers began the variable medication length (TP) (imply period of 9 months) and 301 contributors endured into the 6-month post-treatment follow-up (PTFP).1
Remedy with esketamine NS led to important and significant enhancements in depressive signs, with an average MADRSa exchange from TP baseline to week 4 of –10.3 issues (95% CI: −11.1, −9.5; p<0.001), to week 12 of –14.4 issues (95% CI: −15.4, −13.5; p<0.001), and to week 48 of −17.6 issues (95% CI: −19.4, −15.8; p<0.001).1
“These results reinforce esketamine nasal spray as an effective option for adults with treatment resistant depression, many of whom have spent too long cycling through treatments that don’t meaningfully improve their symptoms”, mentioned Christine Reif-Leonhard, MD, Division of Psychiatry, Psychosomatic Drugs and Psychotherapy, College Health center Frankfurt – Goethe College Frankfurt, Frankfurt am Major, Germany.b “The essential real-world insights gained from the ECHO study complement existing randomised clinical trial findings, further guiding clinical practice and allowing us to optimise personalised treatment pathways for our patients with treatment resistant depression.”
The protection profile was once in keeping with the established profile of esketamine NS2, and not using a new protection alerts recognized.c
The primary real-world information to turn impact sturdiness after sufferers stopped medication
MADRS rankings remained solid after preventing esketamine NS with an average exchange of –1.4 issues from PTFP baseline to week 24.1 This means the sturdiness of impact, as maximum sufferers maintained symptom steadiness and not using a signal of relapse.
“The ECHO study is unique in that, for the first time, we have evaluated the durability of effect in real world practice after stopping esketamine nasal spray treatment in patients with treatment resistant depression. We were thrilled to see sustained symptom stability across the 6-month follow-up period”, mentioned Tamara Werner-Kiechle, MD, Healing Space Head, Neuroscience, Cardiopulmonary and Early Portfolio, Europe, Center East & Africa, Johnson & Johnson. “Creating respite from severe depressive symptoms that lasts beyond the immediate treatment period will significantly improve the lives of people affected, both directly and indirectly, by this devastating disease.”
Figuring out the vital real-world context
Actual-world medication with esketamine NS offered variability in medication publicity, reflecting individualised scientific decision-making and affected person personal tastes.
The imply medication period within the ECHO learn about was once round 9 months with esketamine NS 84 mg being the best possible dose taken in 79.3% of sufferers and probably the most often administered dose in 67.4% of sufferers.1
The actual-world affected person cohort was once clinically advanced with top severity and persistent TRD (>3-year episodes, imply MADRS 33.3), medication resistance (imply of three.8 prior medication screw ups within the present episode), and 45.6% of sufferers had considerable psychiatric comorbidities.1
Round 47% of ECHO learn about contributors weren’t operating, underlining the severity of sickness seen and the real-world implications this may have.1
Editor’s Notes:
The 1st viscount montgomery of alamein-Åsberg Melancholy Ranking Scale (MADRS) is a 10-item, clinician-rated scale used to measure the severity of depressive signs in sufferers with temper problems.3Dr. Christine Reif-Leonhard has equipped consulting and advisory products and services to Johnson & Johnson. She has been remunerated for the media paintings.Remedy-emergent adversarial occasions (TEAEs) have been seen in 81.4% of sufferers, and seven.7% skilled an adversarial tournament which resulted in medication discontinuation. 34.9% of sufferers reported TEAEs with a most severity of gentle. Essentially the most often reported TEAEs have been dissociation (35.1%), dizziness (33.5%) and larger blood drive (21.4%).1
ABOUT THE ECHO RWE STUDYEsketamine CoHOrt (ECHO) is a potential, world, non-interventional Section 4 learn about designed to look at esketamine NS effectiveness and protection in real-world scientific settings.1 It’s the first learn about to judge sturdiness of impact after medication discontinuation with esketamine NS.1 From throughout Europe and Israel, 570 contributors with medication resistant melancholy (TRD) have been enrolled into the medication length, of which 301 participated within the post-treatment follow-up length.1 Imply and median medication length intervals have been 267 days (~9 months) and 190 days (~6 months) respectively, the post-treatment follow-up length was once 24 weeks (~6 months).1 Esketamine NS 84mg was once the best possible dose taken in 79.3% of sufferers and probably the most often administered dose in 67.4%.1
ABOUT MAJOR DEPRESSIVE DISORDER (MDD)Depressive problems have an effect on over 21 million other folks throughout EU international locations.4 The occurrence of melancholy is emerging in Europe and is predicted to change into the main explanation for illness burden globally via 2030.4,5 MDD is characterized via power unhappiness, lack of passion or excitement in day by day actions (anhedonia), and adjustments in sleep and urge for food.6
Roughly one-third of other folks dwelling with MDD were reported to broaden medication resistant melancholy (TRD), that means their melancholy has now not answered to no less than two consecutive, adequately dosed, antidepressants right through the similar depressive episode.7
TRD has a vital damaging have an effect on, emotionally and functionally, at the person and their family members.8,9 The load of TRD is disproportionately upper amongst individuals who don’t reply to antidepressant therapies and is most likely underestimated as a result of there’s restricted revealed analysis on the usage of social products and services and the load for caregivers.8
ABOUT SPRAVATO® (esketamine nasal spray) As an antagonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, esketamine NS has a unique mechanism of motion and drug management in comparison to different licensed melancholy therapies.10,11 Esketamine NS is self-administered, beneath the direct supervision of a healthcare skilled, thru a single-use nasal spray software, for the medication of sufferers inside the approved indications.10 The verdict to prescribe esketamine NS will have to be made up our minds via a psychiatrist.10
Esketamine NS was once permitted via the Eu Fee in December 2019 to be used together with a selective serotonin reuptake inhibitor (SSRI) or serotonin–norepinephrine reuptake inhibitor (SNRI) in grownup sufferers with TRD who’ve now not answered to no less than two other therapies with antidepressants within the present reasonable to critical depressive episode.10 It’s also licensed for co-administered use with oral antidepressant treatment in adults with a reasonable to critical episode of MDD, as acute temporary medication, for the fast aid of depressive signs, which in step with scientific judgement represent a psychiatric emergency.10
For a complete listing of difficult occasions and knowledge on dosage and management, contraindications and different precautions when the use of esketamine nasal spray please check with the Abstract of Product Traits.
ABOUT JOHNSON & JOHNSONAt Johnson & Johnson, we imagine well being is the whole lot. Our power in healthcare innovation empowers us to construct a global the place advanced sicknesses are avoided, handled, and cured, the place therapies are smarter and no more invasive, and answers are private. Via our experience in Leading edge Drugs and MedTech, we’re uniquely situated to innovate around the complete spectrum of healthcare answers nowadays to ship the breakthroughs of the next day to come and profoundly have an effect on well being for humanity.
CAUTIONS CONCERNING FORWARD-LOOKING STATEMENTS
This press liberate accommodates “forward-looking statements” as outlined within the Non-public Securities Litigation Reform Act of 1995 associated with SPRAVATO®. The reader is cautioned to not depend on those forward-looking statements. Those statements are in keeping with present expectancies of long run occasions. If underlying assumptions turn out erroneous or identified or unknown dangers or uncertainties materialize, precise effects may range materially from the expectancies and projections of Johnson & Johnson. Dangers and uncertainties come with, however don’t seem to be restricted to: festival, together with technological advances, new merchandise and patents attained via competition; uncertainty of business luck for brand spanking new merchandise; the power of the corporate to effectively execute strategic plans; have an effect on of commercial mixtures and divestitures; demanding situations to patents; adjustments in behaviour and spending patterns or monetary misery of shoppers of well being care services; and international well being care reforms and tendencies towards well being care value containment. An extra listing and outlines of those dangers, uncertainties and different components may also be present in Johnson & Johnson’s most up-to-date Annual Document on Shape 10-Okay, together with within the sections captioned “Cautionary Note Regarding Forward-Looking Statements” and “Item 1A. Risk Factors,” and in Johnson & Johnson’s next Quarterly Stories on Shape 10-Q and different filings with the Securities and Change Fee.
Copies of those filings are to be had on-line at www.sec.gov, www.jnj.com, www.investor.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does now not adopt to replace any forward-looking commentary on account of new data or long run occasions or tendencies.
Supply: Johnson & Johnson
For Eu clinical and business media simplest. No longer for distribution in the United Kingdom, Eire and BeNeLux.
CP-572382
March 2026
###
REFERENCES
